Zevra Therapeutics, Inc. Common Stock

ZVRA trades at a remarkably compressed 5.12 P/E despite operating in pharmaceuticals, suggesting either deep distress or hidden value—yet the $0.7B market cap and 7.6% short interest indicate skepticism persists. With an RSI of 62, the stock sits in neutral territory without overbought extremes, providing room to run either direction. The valuation multiple is startlingly cheap relative to sector peers, which typically command 15–25x earnings, implying the market prices in significant execution risk or profitability concerns. The modest short position suggests this isn't a heavily contested name, leaving potential catalysts from clinical data or operational improvements largely unhedged by bearish positions.